Trodelvy
| Chemical Name | sacituzumab govitecan-hziy |
| Dosage Form | Injection (intravenous; 180 mg lyophilized powder in single-dose vial) |
| Drug Class | Monoclonal antibodies |
| System | Female reproductive |
| Company | Immunomedics, Inc. |
| Approval Year | 2020 |
Indication
- Indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.